DiscGenics Announces Independent DSMB Safety Review Supports Continuation of Phase III Study of IDCT Without Modifications
The DSMB review was conducted as part of the pre-planned clinical safety oversight process agreed upon with the U.S. FDA.
DiscGenics Treats First Patient in Phase 3 Clinical Trial of IDCT (Rebonuputemcel) for Symptomatic Mild-to-Moderate Lumbar Degenerative Disc Disease
DiscGenics Treats First Patient in Phase 3 Clinical Trial of IDCT (Rebonuputemcel) for Symptomatic Mild-to-Moderate Lumbar Degenerative Disc Disease
DiscGenics and Collaborators Announce Breakthrough in Tissue-Engineered Intervertebral Disc Research
DiscGenics and Collaborators Announce Breakthrough in Tissue-Engineered Intervertebral Disc Research
DiscGenics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to IDCT for Degenerative Disc Disease
DiscGenics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to IDCT for Degenerative Disc Disease
POSITIVE TWO-YEAR CLINICAL DATA ANNOUNCED FOR STUDY OF DISCOGENIC PROGENITOR CELL THERAPY (IDCT) FOR DEGENERATIVE DISC DISEASE
POSITIVE TWO-YEAR CLINICAL DATA ANNOUNCED FOR STUDY OF DISCOGENIC PROGENITOR CELL THERAPY (IDCT) FOR DEGENERATIVE DISC DISEASE
DiscGenics Announces Presentation of Positive Interim Clinical Data from Phase 1/2 Study of Cell Therapy for Degenerative Disc Disease
Allogeneic discogenic cell therapy was well tolerated and produced clinically meaningful, statistically significant improvements in low back pain, function, and quality of life by 12 weeks following intradiscal injection; improvements were sustained at the one-year interim readout with additional data to follow at 18 and 24 months.
DiscGenics Honored by Goldman Sachs for Entrepreneurship
BioUtah member Discgenics Chairman and CEO Flagg Flanagan Among 100 Most Intriguing Entrepreneurs at 2021 Builders + Innovators Summit.
